HopeStage
Back to all studies
CompletedNCT00449397

Quetiapine dose for first-episode psychosis

About this titleRead the official source — NCT00449397
Medication studyAges 15–25AustraliaSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 15 years to 25 years.

Listed locations
MelbourneSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2003
Recruitment status
Completed
Enrollment listed in the registry
150
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Australia
Age range
From 15 Years to 25 Years
Official registry ID
NCT00449397
Official title
Show the full official title

A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Melbourne

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine Fumarate.

Who was this study for?

Listed age limits: 15 years to 25 years.

Want to explore more studies?

Explore studies